delamanid
J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals
An estimated 410,000 people globally developed multidrug- or rifampicin-resistant TB in 2022
Gates Foundation and Wellcome to fund late-stage trial of tuberculosis vaccine candidate
If proven effective, M72 could be the first new tuberculosis vaccine in over a century
Gates MRI and Calibr announce licensing agreement for tuberculosis treatment
TB is a severe disease responsible for an estimated 1.5 million deaths per year
WHO to establish tuberculosis vaccine accelerator council
An estimated 10.6 million contracted TB in 2021, with the disease causing 1.6 million deaths
WHO reveals tuberculosis deaths rose due to COVID-19 disruption
An estimated 10.6 million were infected with TB in 2021, an increase of 4.5% from 2020
Merck and Bill & Melinda Gates Institute sign licensing agreement for tuberculosis candidates
The non-profit will determine their potential for inclusion in new affordable treatment regimens
Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure
The partnership is focused on helping patients with HIV and TB in low- and middle-income countries
GSK licenses its tuberculosis vaccine to Gates MRI
Vaccine has demonstrated around 50% efficacy in preventing disease
Merck strengthens KRAS stake with Taiho and Astex partnership
Partner companies could gain $2.5bn in milestone payments
Otsuka presses on with Alzheimer’s agitation drug
Surprise announcement comes on the heels of phase 3 trial fail
GSK’s pivotal TB vaccine could prevent millions of deaths
Key study took place in TB-endemic regions, testing 3,500 participants
J&J pledges $500m investment into HIV and tuberculosis R&D
Aims to help eliminate both diseases by 2030